Deutsche Bank maintains “buy” rating on GILD

Deutsche Bank reiterated its “buy” rating on Gilead Inc (NASDAQ: GILD). The target price for GILD is maintained at $54. Deutsche Bank believes that the amendment of its treatment guidelines by a major EU HIV advisory committee, the EACS, would have a positive impact on GILD. According to Deutsche Bank, this positive news may ultimately lead to a change in guidelines across the world.

Deutsche Bank expects the amendment by the EACS to boost Gilead’s annual revenues by about $575 million. This will lead to aroung $0.23 rise in GILD’s EPS for a year.